Literature DB >> 33381895

Association of the Leukocyte Immunoglobulin-like Receptor A3 Gene With Neutrophil Activation and Disease Susceptibility in Adult-Onset Still's Disease.

Mengyan Wang1, Mengru Liu1, Jinchao Jia1, Hui Shi1, Jialin Teng1, Honglei Liu1, Yue Sun1, Xiaobing Cheng1, Junna Ye1, Yutong Su1, Huihui Chi1, Tingting Liu1, Zhihong Wang1, Liyan Wan1, Jianfen Meng1, Yuning Ma1, Chengde Yang1, Qiongyi Hu1.   

Abstract

OBJECTIVE: Adult-onset Still's disease (AOSD) is a severe autoinflammatory disease. Neutrophil activation with enhanced neutrophil extracellular trap (NET) formation is involved in the pathogenesis of AOSD. Functional leukocyte immunoglobulin-like receptor A3 (LIR-A3; gene name LILRA3) has been reported to be associated with many autoimmune diseases. We aimed to investigate the association of LILRA3 with disease susceptibility and neutrophil activation in AOSD.
METHODS: The LILRA3 deletion polymorphism and its tagging single-nucleotide polymorphism rs103294 were genotyped in 164 patients with AOSD and 305 healthy controls. The impact of LILRA3 on clinical features and messenger RNA expression was evaluated. Plasma levels of LIR-A3 were detected using enzyme-linked immunosorbent assay (ELISA), and the correlation between LIR-A3 plasma levels and disease activity and levels of circulating NET-DNA was investigated. LIR-A3-induced NETs were determined using PicoGreen double-stranded DNA dye and immunofluorescence analysis in human neutrophils and a neutrophil-like differentiated NB4 cell line transfected with LIR-B2 small interfering RNA.
RESULTS: The findings from genotyping demonstrated that functional LILRA3 was a risk factor for AOSD (11% in AOSD patients versus 5.6% in healthy controls; odds ratio 2.089 [95% confidence interval 1.030-4.291], P = 0.034), and associated with leukocytosis (P = 0.039) and increased levels of circulating neutrophils (P = 0.027). Functional LILRA3 messenger RNA expression was higher in the peripheral blood mononuclear cells (P < 0.0001) and neutrophils (P < 0.001) of LILRA3+/+ patients. Plasma levels of LIR-A3 were elevated in patients with AOSD (P < 0.0001) and correlated with disease activity indicators and levels of circulating NET-DNA complexes. Finally, enhanced NET formation was identified in neutrophils from healthy controls and patients with inactive AOSD after stimulation of the neutrophils with LIR-A3. Moreover, NET formation was impaired in NB4 cells after knockdown of LILRB2 gene expression.
CONCLUSION: Our study provides the first evidence that functional LILRA3 is a novel genetic risk factor for the development of AOSD and that functional LIR-A3 may play a pathogenic role by inducing formation of NETs.
© 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Entities:  

Year:  2021        PMID: 33381895     DOI: 10.1002/art.41635

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  4 in total

Review 1.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

Review 2.  An Update on the Pathogenic Role of Neutrophils in Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.

Authors:  Ji-Won Kim; Mi-Hyun Ahn; Ju-Yang Jung; Chang-Hee Suh; Hyoun-Ah Kim
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

Review 3.  Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.

Authors:  Shijia Rao; Lemuel Shui-Lun Tsang; Ming Zhao; Wei Shi; Qianjin Lu
Journal:  Front Med (Lausanne)       Date:  2022-08-22

Review 4.  Activation mechanisms of monocytes/macrophages in adult-onset Still disease.

Authors:  Hiroto Tsuboi; Seiji Segawa; Mizuki Yagishita; Hirofumi Toko; Fumika Honda; Ayako Kitada; Haruka Miki; Ayako Ohyama; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.